A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells
Chimeric antigen receptor (CAR) T-cell immunotherapy is rapidly emerging as a promising
novel treatment for malignancies. To broaden the success of CAR T-cell treatment for …
novel treatment for malignancies. To broaden the success of CAR T-cell treatment for …
A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells
S Zhou, W Li, Y Xiao, X Zhu, Z Zhong, Q Li… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR) T-cell immunotherapy is rapidly emerging as a promising
novel treatment for malignancies. To broaden the success of CAR T-cell treatment for …
novel treatment for malignancies. To broaden the success of CAR T-cell treatment for …
A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells.
S Zhou, W Li, Y Xiao, X Zhu, Z Zhong, Q Li, F Cheng… - Leukemia, 2020 - europepmc.org
Chimeric antigen receptor (CAR) T-cell immunotherapy is rapidly emerging as a promising
novel treatment for malignancies. To broaden the success of CAR T-cell treatment for …
novel treatment for malignancies. To broaden the success of CAR T-cell treatment for …
A novel chimeric antigen receptor redirecting T-cell specificity towards CD26. sup.+ cancer cells.
S Zhou, W Li, Y Xiao, X Zhu, Z Zhong, Q Li, F Cheng - Leukemia, 2021 - go.gale.com
Chimeric antigen receptor (CAR) T-cell immunotherapy is rapidly emerging as a promising
novel treatment for malignancies. To broaden the success of CAR T-cell treatment for …
novel treatment for malignancies. To broaden the success of CAR T-cell treatment for …